MW 481.8 Da, Purity >98%. Cell-permeable, phenylcyclohexyl-urea based compound that selectively downregulates the expression of p21, independent of p53 expression, at either transcription or post-transcriptional level. Attenuates p21 protein levels with minimal effect on p21 protein stability. Has no significant effect on the activities of Raf kinases, VEGFR2 kinase, or the phosphorylation state of ERK. Effectively inhibits the growth of multiple cancer cell lines (GI50 = ~ 10 μM against NCI60 cell lines).
Select an associated product type
MW 481.8 Da, Purity >98%. Cell-permeable, phenylcyclohexyl-urea based compound that selectively downregulates the expression of p21, independent of p53 expression, at either transcription or post-transcriptional level. Attenuates p21 protein levels with minimal effect on p21 protein stability. Has no significant effect on the activities of Raf kinases, VEGFR2 kinase, or the phosphorylation state of ERK. Effectively inhibits the growth of multiple cancer cell lines (GI50 = ~ 10 μM against NCI60 cell lines).
Soluble in ethanol to 100 mM.
Soluble in DMSO to 100 mM.
Cell-permeable, phenylcyclohexyl-urea based compound that selectively downregulates the expression of p21, independent of p53 expression, at either transcription or post-transcriptional level. Attenuates p21 protein levels with minimal effect on p21 protein stability. Has no significant effect on the activities of Raf kinases, VEGFR2 kinase, or the phosphorylation state of ERK. Effectively inhibits the growth of multiple cancer cell lines (GI50 = ~ 10 μM against NCI60 cell lines).
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2D chemical structure image of ab146969, UC2288, p21 inhibitor
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com